Review Article
Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
Table 3
SENSE trial: summary efficacy and safety results by treatment arm, to Week 48.
| | | Etravirine arm | Efavirenz arm |
| | HIV RNA <50 c/mL, ITT | 60 (76%) | 58 (74%) | | Any Grades 2–4 drug-related adverse event | 21 (27%) | 33 (42%) | | Adverse events leading to discontinuation | 6 (8%) | 13 (17%) | Grades 2–4 drug-related clinical adverse
events of interest | | | | Nervous system | 1 (1%) | 13 (17%) | | Psychiatric | 4 (5%) | 12 (15%) | | Skin or subcutaneous disorders | 9 (11.4%) | 9 (11.5%) | | Grades 3-4 laboratory abnormalities | | | | Hypophosphatemia | 0 | 4 (5%) | | Neutropenia | 6 (8%) | 3 (4%) | | Elevated ALT | 2 (3%) | 1 (1%) | | Elevated AST | 1 (1%) | 2 (3%) | | Elevated total cholesterol | 1 (1%) | 6 (8%) | | Elevated LDL | 2 (3%) | 8 (10%) | | Elevated triglycerides | 0 | 2 (3%) |
|
|
, comparison between treatment arms at Week 48.
|
